ASH Lymphoma 2018

Cancer Network presents exclusive coverage from the 60^th Annual American Society of Hematology (ASH) Meeting & Exhibition, held December 1–4 in San Diego, California. We bring you interviews with experts in the field and on-site reports as we cover the latest research, trials, and scientific advances changing the way different types of lymphoma are managed and treated.

ASH Lymphoma

Promising New Prognostic Score for High-Risk DLBCL

December 18, 2018

Naveed Saleh, MD, MS

Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.

READ >>

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma

December 6, 2018

Traci DeVito

The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

READ >>

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients

December 5, 2018

Naveed Saleh, MD, MS

Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.

READ >>

Can Venetoclax Plus R-CHOP Improve Outcomes in Aggressive DLBCL?

December 5, 2018

Naveed Saleh, MD, MS

In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.

READ >>

A Better Risk Model for DLBCL Patients?

December 3, 2018

Naveed Saleh, MD, MS

Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.

READ >>

Using Clonal Hematopoiesis to Assess Risk in Lymphoma Patients

December 3, 2018

Naveed Saleh, MD, MS

Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.

READ >>

Rituximab Does Not Improve Outcomes in Primary CNS Lymphoma

December 16, 2017

Bryant Furlow

Adding rituximab to MBVP induction chemotherapy does not improve outcomes for patients with primary central nervous system lymphoma.

READ >>

DLBCL Trials May Exclude Patients Who Need Novel Therapies Most

December 12, 2017

Matthew J. Maurer, MS

In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.

READ >>

Brentuximab Vedotin Improves Standard Regimen for Advanced Hodgkin Lymphoma

December 10, 2017

Leah Lawrence

Patients with Hodgkin lymphoma treated with a drug combination including brentuximab vedotin achieved superior progression-free survival, with a reduction in the risk for progression, death, or need for additional anticancer therapy, compared with the standard four-drug chemotherapy regimen.